In addition to mutations affecting the MAPK pathway, mutation of PIK3CA, which encodes PI3K in the PI3K-AKT-mTOR (mTOR: mammalian target of rapamycin) pathway, was discovered in 1 (1.2%) of 86 LCH patients [43]. This evidence concerns the gene MTOR and Langerhans cell histiocytosis.